Novel phospholipolytic activities associated with electronegative low-density lipoprotein are involved in increased self-aggregation

Biochemistry. 2008 Aug 5;47(31):8186-94. doi: 10.1021/bi800537h. Epub 2008 Jul 8.

Abstract

Electronegative low-density lipoprotein (LDL(-)) is a minor LDL subfraction present in plasma with increased platelet-activating factor acetylhydrolase (PAF-AH) activity. This activity could be involved in the proinflammatory effects of LDL(-). Our aim was to study the presence of additional phospholipolytic activities in LDL(-). Total LDL was fractionated into electropositive (LDL(+)) and LDL(-) by anion-exchange chromatography, and phospholipolytic activities were measured by fluorometric methods. Phospholipolytic activity was absent in LDL(+) whereas LDL(-) presented activity against lysophosphatidylcholine (LPC, 82.4 +/- 34.9 milliunits/mg of apoB), sphingomyelin (SM, 53.3 +/- 22.5 milliunits/mg of apoB), and phosphatidylcholine (PC, 25.7 +/- 4.3 milliunits/mg of apoB). LDL(-), but not LDL(+), presented spontaneous self-aggregation at 37 degrees C in parallel to phospholipid degradation. This was observed in the absence of lipid peroxidation and suggests the involvement of phospholipolytic activity in self-aggregation of LDL(-). Phospholipolytic activity was not due to PAF-AH, apoE, or apoC-III and was not increased in LDL(+) modified by Cu (2+) oxidation, acetylation, or secretory phospholipase A 2 (PLA 2). However, LDL(-) efficiently degraded phospholipids of lipoproteins enriched in LPC, such as oxidized LDL or PLA 2-LDL, but not native or acetylated LDL. This finding supports that LPC is the best substrate for LDL(-)-associated phospholipolytic activity. These results reveal novel properties of LDL(-) that could play a significant role in its atherogenic properties.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anion Exchange Resins / chemistry
  • Apolipoprotein C-III / pharmacology
  • Apolipoproteins E / pharmacology
  • Bridged-Ring Compounds / pharmacology
  • Chromatography, Ion Exchange
  • Enzyme Activation / drug effects
  • Hydrogen-Ion Concentration
  • Lipolysis / drug effects
  • Lipolysis / physiology*
  • Lipoproteins, LDL / chemistry
  • Lipoproteins, LDL / metabolism*
  • Lysophosphatidylcholines / chemistry
  • Lysophosphatidylcholines / metabolism
  • Magnesium / metabolism
  • Norbornanes
  • Phosphatidylcholines / chemistry
  • Phosphatidylcholines / metabolism
  • Phosphodiesterase Inhibitors / pharmacology
  • Phospholipids / chemistry
  • Phospholipids / metabolism*
  • Sphingomyelins / chemistry
  • Sphingomyelins / metabolism
  • Sulfones / pharmacology
  • Thiocarbamates
  • Thiones / pharmacology
  • Time Factors

Substances

  • Anion Exchange Resins
  • Apolipoprotein C-III
  • Apolipoproteins E
  • Bridged-Ring Compounds
  • Lipoproteins, LDL
  • Lysophosphatidylcholines
  • Norbornanes
  • Phosphatidylcholines
  • Phosphodiesterase Inhibitors
  • Phospholipids
  • Sphingomyelins
  • Sulfones
  • Thiocarbamates
  • Thiones
  • 4-(2-aminoethyl)benzenesulfonylfluoride
  • tricyclodecane-9-yl-xanthogenate
  • Magnesium